TY - T1的为期两年的复发率在前研究:女士更完备的队列(P01.132) JF -神经学乔-神经病学SP - P01.132 LP - P01.132六世- 78 - 1补充A首页U -帕特丽夏Coyle AU -霍华德Zwibel盟-布鲁斯·科恩AU -托马斯Leist AU -马克Tullman AU -克莱德马科维茨AU -玛丽·休斯Y1 - 2012/04/23 UR - //www.ez-admanager.com/content/78/1_Supplement/P01.132.abstract N2 -目的:评估特征相关2年复发率最高的女士更完备的队列研究。背景治疗优化研究女士(女士)是一种潜在的,非盲平行小组研究的病人正在接受治疗疾病修饰治疗(DMT)。所有的DMT已经被证明能够有效地降低复发率。设计/方法:确定最高女士潜在参与者与药物疗法专业药房管理计划。签署知情同意表格返回给药房,和学习研究网站登记注销生产指令。在基线和每月的间隔超过24个月,注册参与者收到提醒对调查作出回应。自我报告的反应是直接进入到研究数据库。结果:顶部女士完成者队列由531名受试者疾病的平均持续时间为11.1 + 9.2年。近90%的参与者符合复发的标准形式的女士这个队列的2年复发率为35.3%。Glatiramer醋酸被使用了50.8%,49.2%的人使用β干扰素研究招生。在两年内治疗变化发生了50例(9.4%),明显与确诊复发(chi2 = 13.9, df = 2, p =措施)。 While mean duration of current DMT treatment was 4.3+4.1 years, shorter duration was correlated with more confirmed relapses (p = .004). One-third of the completer cohort had used other DMT prior to starting their current therapy (mean number of previous therapies: 1.3) and number of previous DMT was positively correlated with number of confirmed relapses (p = .001). Disease duration and enrollment DMT were not associated with relapses.Conclusions: The two-year relapse rate in the completer cohort of the TOP MS Study was influenced by change in DMT therapy, time on DMT treatment, and number of previous DMT treatments.Supported by: Teva Pharmaceuticals.Disclosure: Dr. Coyle has received personal compensation for activities with Acorda Therapeutics, Avanir Pharmaceuticals, Bayer Pharmaceuticals Corporation, Biogen Idec, Genzyme Corporation, Novartis, Questcor, Roche Diagnostics Corporation, Sanofi-Aventis Pharmaceuticals, Inc., and Teva Neuroscience. Dr. Coyle has received personal compensation in an editorial capacity for NEURA. Dr. Coyle has received research support from Serono, Inc., Novartis, and Sanofi-Aventis Pharmaceuticals, Inc. Dr. Zwibel has received personal compensation for activities with Serono, Inc., and Teva Neuroscience. Dr. Zwibel has received research support from Teva Neuroscience. Dr. Cohen has received research support from Biogen Idec. Dr. Leist has received personal compensation for activities with EMD Serono, Teva Neuroscience and Bayer.Dr. Leist has received research support from Bayer, EMD Serono and Teva Neuroscience. Dr. Tullman has received personal compensation for activities with Acorda Therapeutics, Biogen Idec, Serono Inc., Novartis, Pfizer Inc., Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Abbott Labortories, Inc. and Vaccinex as a consultant and/or speaker. Dr. Tullman has received research support from Acorda Therapeutics, BioMS, Novartis, and Genentech, Inc. Dr. Markowitz has received personal compensation for activities with Bayer, Teva, EMD-Serono, Biogen Idec, and Eli Lilly. Dr. Hughes has received research support from Teva Neuroscience, Berlex Labratories and Genentech, Inc..Monday, April 23 2012, 14:00 pm-18:30 pm ER -